

# 9<sup>th</sup> IAU and UCL Urology Conference

Holiday Inn London Regent's Park

September 25 – 27 2020, London



## Abstract Submission

Online submission for the upcoming 9<sup>th</sup> IAU and UCL Annual Conference is now open. Each abstract will be scored by three reviewers and all abstracts will be accepted on the basis of scientific merit.

### Key Dates

Call for abstracts opens	Monday 17 <sup>th</sup> February 2020
Call for abstracts closes	Monday 15 <sup>th</sup> June 2020
Notification to authors of abstract acceptance	Monday 13 <sup>th</sup> July 2020
Author acceptance deadline	Monday 3 <sup>rd</sup> August 2020
Final program released	Friday 21 <sup>st</sup> August 2020
Presenter registration deadline	Friday 28 <sup>th</sup> August 2020

### Abstract Themes

- PCNL
- URS
- SWL
- Basic Research
- Metabolic evaluation and drug treatment
- Video:
  - Epidemiology of Urolithiasis
  - Training and Education
  - Other

There is a maximum of 5 abstract submissions per person allowed.

### Rules for Authors

#### Prior Publication of Material:

The IAU and UCL Conference is a forum for the presentation of novel research findings. The work covered by the abstract must not have been published (manuscript or abstract) before September 20<sup>th</sup> 2020. If the work has been presented at another meeting, the author must disclose when and where it was presented (during submission process). This is so the Abstract Review Committee can make its decision based on all available details.

#### Objectivity:

The IAU is committed to offering participants an open forum for scientific discussion, wherein all scientists and clinicians are invited to contribute actively. To preserve this valuable environment, the IAU urges all presenters to avoid statements, symbols or other displays that are subjective and unscientific in nature.

### **Abstract Acceptance:**

Each abstract will be scored by three reviewers. Abstract will be accepted on the basis of scientific merit.

### **Abstract Revisions:**

Abstracts may not be revised or resubmitted after the deadline of Monday 15<sup>th</sup> June 2020.

### **Abstract Withdrawal:**

Please submit abstract withdrawal requests in writing by Monday 15<sup>th</sup> June 2020.

### **Change of Presenting Author:**

Please submit requests in writing by Monday 15<sup>th</sup> June 2020. After this date, changes will no longer appear in the IAU Abstract Book.

### **Publication and Copyright:**

All accepted abstracts will be published in the IAU Abstract Book. Publication of abstracts implies transfer of copyright of the article to the publisher. This will ensure the widest possible protection and dissemination of information under copyright laws.

### **Preparation of Abstracts**

#### **Language:**

Abstracts must be written and presented in English. Careful typing and proof reading are essential.

#### **Word Count:**

Abstracts should not exceed 350 words. Deduct 50 words for each table or graph included.

#### **Abstract Themes:**

To ensure that your abstract receives proper scientific consideration, be sure to note the appropriate abstract theme as indicated below:

- PCNL
- URS
- SWL
- Basic Research
- Metabolic evaluation and drug treatment
- Video:
  - Epidemiology of Urolithiasis
  - Training and Education
  - Other

### **Images, Tables and Graphs:**

Images are not permitted, as they do not reproduce well. Brief and clear tables or graphs are accepted.

### **Digital Video Submissions:**

**Content** – all digital videos must be recorded in English and have some sound. The opening of the presentation should begin with the title and all the authors' full names. It is important that all videos must be accompanied by a written abstract.

**Length** – all videos must not exceed 5 minutes in total length. Any videos that are longer than 5 minutes in durations will be automatically rejected.

**Format and Quality** – It is important that the overall quality of the video is as high as possible. All submitted videos will be reviewed initially for picture and sound quality. Any videos that have poor sound and picture quality will be excluded from consideration regardless of the quality of content.

**File Type and Size** – The maximum file limit for video is 350mb. The preferred format for video submission is MP4 as this has the strongest quality. We can also accept PowerPoint presentations with video embedded into the presentation, but the file size must not be greater than 350mb. Please consider compressing or "zip" video files before uploading to the Abstract site.

### **Drug Names**

Please use generic drug names in your abstract submission.

Standard abbreviations may be used without definition. Non-standard abbreviations should be kept to a minimum and placed in parentheses after the first use of the word or phrase.

### **Abstract Title:**

Abstracts must have a short, specific title (no abbreviations) that indicates the nature of the investigation.

### **Sections:**

Abstracts MUST include the following four distinct sections:

- Introduction and Objective
- Materials and Methods
- Results
- Conclusion

### **Acknowledgments:**

Do not include any references, credits or grant support

**Abstract Data:**

Abstracts that describe single clinical cases or investigations of compounds that involve inadequate numbers of study subjects, or abstracts that lack quantitative data will not be accepted. Authors should not “split” data to create several abstracts from one. If splitting is judged to have occurred, priority scores of related abstracts will be reduced.

Abstracts containing identical or nearly identical data submitted from the same institution (and/or individuals) describing the same study population will be disqualified.

Statements such as “results will be discussed” will automatically disqualify the abstract. Reviewers require specific data on which to base their evaluation. Please bear in mind that your abstract will be rated according to the following criteria:

- Is the design of the study valid?
- Are the methods appropriate?
- What is the significance of the results?
- Is the event described in the case report significant?

**Human Experimentation:**

Any human experimentation conducted as part of the submitted abstract(s) must follow the protocol approved by the institutional or local committee on ethics in human investigation, or, if no such committee exists, the investigation should have been conducted in accordance with the principles of the World Medical Association’s Helsinki Declaration. The Scientific Committee may inquire further into ethical aspects when evaluating the abstract(s).